Efficacy of the GluK1/AMPA Receptor Antagonist LY293558 against Seizures and Neuropathology in a Soman-Exposure Model without Pretreatment and its Pharmacokinetics after Intramuscular Administration

MLA

Vassiliki Aroniadou-Anderjaska, et al. “Efficacy of the GluK1/AMPA Receptor Antagonist LY293558 against Seizures and Neuropathology in a Soman-Exposure Model without Pretreatment and Its Pharmacokinetics after Intramuscular Administration.” Journal of Pharmacology and Experimental Therapeutics, vol. 344, Oct. 2012, pp. 133–40. EBSCOhost, https://doi.org/10.1124/jpet.112.198689.

APA

Vassiliki Aroniadou-Anderjaska, Taiza H. Figueiredo, James P. Apland, Carol E. Green, Chun Yang, Maria F. M. Braga, Felicia Qashu, & Robert Swezey. (2012). Efficacy of the GluK1/AMPA Receptor Antagonist LY293558 against Seizures and Neuropathology in a Soman-Exposure Model without Pretreatment and its Pharmacokinetics after Intramuscular Administration. Journal of Pharmacology and Experimental Therapeutics, 344, 133–140. https://doi.org/10.1124/jpet.112.198689

Chicago

Vassiliki Aroniadou-Anderjaska, Taiza H. Figueiredo, James P. Apland, Carol E. Green, Chun Yang, Maria F. M. Braga, Felicia Qashu, and Robert Swezey. 2012. “Efficacy of the GluK1/AMPA Receptor Antagonist LY293558 against Seizures and Neuropathology in a Soman-Exposure Model without Pretreatment and Its Pharmacokinetics after Intramuscular Administration.” Journal of Pharmacology and Experimental Therapeutics 344 (October): 133–40. doi:10.1124/jpet.112.198689.